Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes.

Citation data:

Journal of controlled release : official journal of the Controlled Release Society, ISSN: 1873-4995, Vol: 268, Page: 305-313

Publication Year:
2017
Usage 1
Abstract Views 1
Social Media 440
Shares, Likes & Comments 428
Tweets 12
PMID:
28860072
DOI:
10.1016/j.jconrel.2017.08.035
Author(s):
Nurunnabi, Md, Lee, Seung-Ah, Revuri, Vishnu, Hwang, Yong Hwa, Kang, Sung Hun, Lee, Minhyung, Cho, Sungpil, Cho, Kwang Jae, Byun, Youngro, Bae, You Han, Lee, Dong Yun, Lee, Yong-Kyu Show More Hide
Publisher(s):
Elsevier BV
Tags:
Pharmacology, Toxicology and Pharmaceutics
Most Recent Tweet View All Tweets
article description
The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.

This article has 0 Wikipedia mention.